Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2 Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of LSALT Peptide for the Prevention or Attenuation of Acute Kidney Injury (AKI) in Patients Undergoing On-Pump Cardiac Surgery

Next Previous
Trial Profile

Phase 2 Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of LSALT Peptide for the Prevention or Attenuation of Acute Kidney Injury (AKI) in Patients Undergoing On-Pump Cardiac Surgery

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Sep 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs LSALT peptide (Primary)
  • Indications Acute kidney injury
  • Focus Therapeutic Use
  • Acronyms CS-AKI
  • Sponsors Arch Biopartners

Most Recent Events

  • 31 Aug 2026 According to an Arch Biopartners media release,Arch recently announced that the Company will expand the study into the United States following interest from clinicians at five leading institutions. The central IRB approval completes an important step toward activating these U.S. sites.
  • 31 Aug 2026 According to an Arch Biopartners media release, company announced that it has received central Institutional Review Board (IRB) approval of the protocol and related study documents for the Companys ongoing Phase II trial of LSALT peptide targeting cardiac surgery-associated acute kidney injury
  • 11 Aug 2026 According to an Arch Biopartners media release, company announced it will expand this trial into the United States, following interest from clinicians at five leading U.S. institutions.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top